Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%
Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%
Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%; Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments
Affimed在ASH会议上宣布，Acimtamig与AlloNk联合治疗在22名重度预处理的复发/难治性经典霍奇金淋巴瘤患者中，整体反应率为86%；完全反应率为55%，这些患者已用尽所有标准治疗。
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination of acimtamig (AFM13) with Artiva Biotherapeutics' allogeneic NK cell AlloNK in patients with R/R cHL.
Affimed N.V.（纳斯达克：AFMD）是一家临床阶段的免疫肿瘤学公司，致力于让患者恢复与生俱来的抗癌能力。今天在第66届ASH年度会议和博览会上宣布了一组数据的海报展示。该数据集包括来自LuminICE-203（AFM13-203）第二阶段开放标签、多中心、多队列研究的28名患者的运行阶段。这项试验评估了Acimtamig（AFM13）与Artiva生物治疗的异基因Nk细胞AlloNk联合治疗在复发/难治性经典霍奇金淋巴瘤患者中的安全性和有效性。
Acimtamig in combination with AlloNK demonstrated a high overall response rate (ORR) of 86% with complete response (CR) of 55%. All patients in the study were heavily pretreated with a median of 5 (range: 2-13) prior therapies. All patients had received intensive combination chemotherapy, PD(L)1 checkpoint inhibitors and brentuximab vedotin. In addition, about two third of the patients had also received a previous stem cell transplant. The combination regimen exhibited a well-managed safety profile with no unexpected safety signals. Importantly, no cases of graft-versus-host disease (GvHD) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported.
Acimtamig与AlloNk联合显示出86%的高整体反应率（ORR）和55%的完全反应（CR）。研究中的所有患者均为重度预处理，之前治疗的中位数为5（区间：2-13）。所有患者均接受了强度结合化疗、PD（L）1检查点抑制剂和布伦图单抗。此外，约三分之二的患者还接受过以前的干细胞移植。联合治疗方案表现出良好的安全性管理，没有意外的安全信号。重要的是，未报告任何移植物抗宿主病（GvHD）或免疫效应细胞相关神经毒性综合征（ICANS）病例。
